vaccine efficacy – Medxy AI

Nucleoside-Modified mRNA Influenza Vaccine Prevents Symptomatic and Febrile Illness in a Human Challenge Model

By MedXY 12/06/2025

A phase 2a human challenge trial found a nucleoside‑modified mRNA influenza vaccine provided complete protection against symptomatic and febrile A/H1N1 infection versus unvaccinated controls and reduced viral load versus control and QIV, with no serious adverse events.

Infectious Diseases news Public Health

Pfizer’s Modified mRNA Quadrivalent Influenza Vaccine Demonstrates 34.5% Relative Efficacy vs Licensed Inactivated Vaccine in Phase 3 Trial

By MedXY 11/21/2025

A phase 3 trial of Pfizer’s quadrivalent modified mRNA influenza vaccine (n≈18,476) showed 34.5% relative efficacy vs a licensed inactivated vaccine for laboratory-confirmed influenza (A strains) with higher reactogenicity but low rates of serious adverse events.

Infectious Diseases news Respiratory

Three-Season Protection Against RSV in Older Adults: Insights from the AReSVi-006 Phase 3 Trial of the AS01E-Adjuvanted RSVPreF3 OA Vaccine

By MedXY 10/04/2025

The AS01E-adjuvanted RSVPreF3 OA vaccine demonstrates robust efficacy against RSV-related lower respiratory tract disease over three seasons in adults aged 60+, with a favorable safety profile and promising immunogenicity findings.